Modus Therapeutics Holding AB (publ) (MODTX.ST)
SEK 1.24
(-2.75%)
SEK 1.24
(-2.75%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 20.04 Million SEK | 77.81% |
| 2022 | 11.27 Million SEK | -46.81% |
| 2021 | 21.19 Million SEK | 182.89% |
| 2020 | 7.49 Million SEK | 265.24% |
| 2019 | 2.05 Million SEK | -95.63% |
| 2018 | 46.95 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 12.51 Million SEK | -21.79% |
| 2024 Q1 | 16 Million SEK | -20.13% |
| 2023 Q2 | 5.6 Million SEK | -23.76% |
| 2023 Q1 | 7.35 Million SEK | -34.76% |
| 2023 FY | 20.04 Million SEK | 77.81% |
| 2023 Q3 | 5.28 Million SEK | -5.71% |
| 2023 Q4 | 20.04 Million SEK | 279.13% |
| 2022 Q3 | 19.37 Million SEK | 79.54% |
| 2022 FY | 11.27 Million SEK | -46.81% |
| 2022 Q4 | 11.27 Million SEK | -41.82% |
| 2022 Q2 | 10.79 Million SEK | -19.81% |
| 2022 Q1 | 13.45 Million SEK | -36.51% |
| 2021 FY | 21.19 Million SEK | 182.89% |
| 2021 Q4 | 21.19 Million SEK | -28.1% |
| 2021 Q3 | 29.47 Million SEK | 582.88% |
| 2021 Q2 | 4.31 Million SEK | -33.48% |
| 2021 Q1 | 6.48 Million SEK | -13.39% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q4 | 7.49 Million SEK | 0.0% |
| 2020 FY | 7.49 Million SEK | 265.24% |
| 2019 FY | 2.05 Million SEK | -95.63% |
| 2018 FY | 46.95 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | 83.732% |
| Amniotics AB (publ) | 26.08 Million SEK | 23.173% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -229.784% |
| BioArctic AB (publ) | 1.18 Billion SEK | 98.31% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.946% |
| Saniona AB (publ) | 64.14 Million SEK | 68.756% |
| Simris Alg AB (publ) | 174.55 Million SEK | 88.519% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 95.961% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -34.784% |
| NextCell Pharma AB | 81.28 Million SEK | 75.346% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 33.58% |
| AcouSort AB (publ) | 34.51 Million SEK | 41.932% |
| Active Biotech AB (publ) | 44 Million SEK | 54.452% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 83.081% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.95% |
| Cantargia AB (publ) | 223.71 Million SEK | 91.042% |
| Genovis AB (publ.) | 288.85 Million SEK | 93.062% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 76.485% |
| Mendus AB (publ) | 755.95 Million SEK | 97.349% |
| Kancera AB (publ) | 65.64 Million SEK | 69.47% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 98.407% |
| LIDDS AB (publ) | 17.65 Million SEK | -13.515% |
| Lipum AB (publ) | 12.11 Million SEK | -65.491% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 40.358% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 92.81% |
| OncoZenge AB (publ) | 20.34 Million SEK | 1.47% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 96.933% |
| Xintela AB (publ) | 18.39 Million SEK | -8.948% |
| Ziccum AB (publ) | 14.97 Million SEK | -33.857% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 85.746% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 97.381% |
| CombiGene AB (publ) | 120.61 Million SEK | 83.384% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 90.766% |
| Intervacc AB (publ) | 259.61 Million SEK | 92.28% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 67.871% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 52.237% |
| Corline Biomedical AB | 100.1 Million SEK | 79.98% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 88.685% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 67.755% |
| Aptahem AB (publ) | 63.02 Million SEK | 68.201% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 94.296% |
| Fluicell AB (publ) | 9.34 Million SEK | -114.572% |
| Biovica International AB (publ) | 131.4 Million SEK | 84.749% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 62.176% |
| Abliva AB (publ) | 87.49 Million SEK | 77.096% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 97.364% |
| 2cureX AB (publ) | 16.62 Million SEK | -20.547% |
| I-Tech AB | 152.44 Million SEK | 86.853% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 98.031% |
| Cyxone AB (publ) | 43.65 Million SEK | 54.092% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 74.532% |
| Biosergen AB | 7.2 Million SEK | -178.309% |
| Nanologica AB (publ) | 77.42 Million SEK | 74.117% |
| SynAct Pharma AB | 228.01 Million SEK | 91.211% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 25.117% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.569% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 7.657% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 91.593% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -137.031% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 76.983% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 29.7% |